Thank you for sharing!

Your article was successfully shared with the contacts you provided.
Name and title: John E. Osborn, senior vice president, general counsel and secretary Age: 47 The company: Cephalon Inc., a Nasdaq 100 firm, was established in 1987 and is now rated eighth in biotechnology revenues among worldwide life sciences companies. It discovers, develops and markets products used to treat neurological, movement and sleep disorders, including multiple sclerosis, narcolepsy and Alzheimer’s disease. Cephalon also produces pharmaceuticals for cancer and pain relief. Its nearly 2,500 employees are based at corporate headquarters in West Chester, Penn., manufacturing facilities in Utah and Minnesota, and offices in Europe. Cephalon launched its first commercial product-Provigil, a wakefulness-promoting agent-in 1999 and currently markets three proprietary products domestically and 20 internationally. It has generated revenues approaching $1 billion in 2004. Does it all: Osborn, a self-described “generalist,” oversees Cephalon’s legal agenda, handles intellectual property matters and manages the firm’s corporate communications and government and public affairs. He evaluates licensing, acquisitions and other commercial opportunities. The GC is active in the pharmaceutical policy realm and participates with professional lobbyists in selected federal and state lobbying activities. Cephalon’s legal department assists its clinical research group in drafting and negotiating research agreements, and Osborn reviews and approves promotional and marketing materials, paying careful attention to product labeling. He works with vigilance organizations, such as the Food and Drug Administration Advisory Committee, to monitor drug safety. Osborn said that “life sciences is oriented toward transactions, deal-making and collaborations, which is at the heart of who I am.” He coordinated merger-clearance efforts in Cephalon’s acquisition of CIMA Labs Inc. and worked with Dechert’s Paris office as lead negotiator in the purchase of Laboratoire L. Lafon. Significant developments: In 1984, Congress attempted to strike a balance between the intellectual property rights of proprietary pharmaceutical and biotech companies and the ability of generic firms to introduce competing products. This tug of war is an “ongoing theme” for the industry and Cephalon, which markets “small-molecule products” that are subject to generic competition. Osborn described the law as it relates to the sale and marketing of pharmaceuticals as “generally unsettled.” He said that several federal opinions have established that companies have commercial free speech rights to communicate valid scientific and medical information. However, he said, in the wake of a controversial settlement between Pfizer Inc. and Warner-Lambert Co. over the marketing of the drug Neurontin, observers believe that some industry members are still engaged in inappropriate marketing activities. In March 2003, in the U.S. district court in Newark, N.J., Cephalon brought suit against four generic companies (Teva Pharmaceuticals USA Inc., Mylan Pharmaceutical Inc., Ranbaxy Pharmaceuticals Inc. and Barr Laboratories Inc.), alleging patent infringement of the form of modafinil contained in its proprietary drug Provigil. The case is still pending. Legal team: The GC manages a 24-member staff consisting of 13 lawyers and 11 paralegals and administrative assistants. Four attorneys concentrate on intellectual property, and six delve into various regulatory issues, litigation, mergers and acquisitions and commercial licensing. Three lawyers are stationed in Cephalon’s offices in the United Kingdom and France. Osborn reports to Frank Baldino, Cephalon’s chief operating officer, and interfaces with the board of directors, committee chairs and the nominating committee. “We handle a substantial amount of day-to-day work” in-house, said Osborn, who hires outside attorneys for litigation, antitrust matters and acquisitions. His predecessor was a partner with Morgan, Lewis & Bockius, so “in the early days, we relied broadly upon them.” Osborn has “gradually and selectively broadened the number of firms” used by Cephalon, and the roster now includes Morgan Lewis, Dechert, Sidley Austin Brown & Wood, Washington’s Hogan & Hartson, Atlanta’s King & Spalding and Wilmer Cutler Pickering Hale and Dorr. Route to the top: Osborn received his undergraduate degree from the University of Iowa (1979) and then attended the University of Virginia School of Law (1983). He also received a master’s degree in intellectual public policy from Johns Hopkins University (1992) and did postgraduate study at Princeton University (1997-1999). In 1983, he served as a law clerk to Judge Albert V. Bryan of the 4th U.S. Circuit Court of Appeals in Alexandria, Va. He then moved to Hale and Dorr where, until 1988, he concentrated in corporate securities and gained biotechnology exposure. In 1989, he was appointed a special assistant in international legal and policy issues at the U.S. Department of State, and he returned to the private sector in 1992 as a division counsel with DuPont Merck Pharmaceutical Co., a joint venture. Osborn joined Cephalon in 1997, becoming its chief legal officer a year later. Prior to embarking on his law career, he worked in the Congressional Budget Office and the offices of Representative Jim Leach, R-Iowa, and Senator John Heinz, R-Penn. He recently was appointed by Secretary of State Colin L. Powell to serve on the governing board of the East-West Center of Honolulu, an education and research organization devoted to the development of the Asia-Pacific region and its relationship with the United States. Personal: Iowa native Osborn and his wife, Deborah Lynn Powell, are the parents of two daughters, Delaney, 13, and Keeley, 4. He enjoys golf, tennis and trips to Nantucket, Mass. Last book and movie: The Rule of Four, by Ian Caldwell and Dustin Thomason, and The Village.

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2020 ALM Media Properties, LLC. All Rights Reserved.